get ready for blastoff, page-14

A snipit from The Australian newspaper today..

" biotech Daily sage Mark Sinatra etmates the testosterone replacement market could be worth US 1.4 - 1.6bn by 2012, a year after Axiron's planned launch. Assuming 10% market share and a 20% royalty rate, this equates to $US 28- 32Mil. If Axiron grabs a 50% share, this rises to $US140- $US160mil.

We had Acrux as a long term buy at $2.42 in March. Given the time lag involved in royalties flowing, we suggest myopic investors take profits. Otherwise it's a HOLD.

The full take on this story is on today's Australian paper by Tim Boreham.

DYOR